Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-11-14

Clinical Trial Update: BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for BI 409306 in cognitive impairment due to Alzheimer’s disease; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BI 409306

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Alzheimer Disease | Phase 2 | Status: COMPLETED | Results posted: 2018-11-14